Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer

NCT03936270 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Palbociclib 125mg
DRUG: Letrozole 2.5mg

Sponsor

Latin American Cooperative Oncology Group

Collaborators

[object Object]